Roles > EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
Page last updated: 2024-08-05 15:40:04
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
An EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of cytochrome P450 17-alpha-hydroxylase/C17,20-lyase (EC 1.14.99.9).
ChEBI ID: 68640
Members (2)
| Member | Definition | Class |
|---|
| abiraterone | A 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer. | abiraterone |
| abiraterone acetate | A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer. | abiraterone acetate |
Research
Studies (1,494)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (0.27) | 18.2507 |
| 2000's | 28 (1.87) | 29.6817 |
| 2010's | 1,010 (67.60) | 24.3611 |
| 2020's | 452 (30.25) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|
| Trials | 234 (14.32%) | 5.53% |
| Reviews | 320 (19.58%) | 6.00% |
| Case Studies | 60 (3.67%) | 4.05% |
| Observational | 40 (2.45%) | 0.25% |
| Other | 980 (59.98%) | 84.16% |
Protein Targets (14)
Potency Measurements
Inhibition Measurements
Activation Measurements